Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk of relapse in adult patients with multiple sclerosis treated with dimethyl fumarate versus fingolimod and teriflunomide

Trial Profile

Risk of relapse in adult patients with multiple sclerosis treated with dimethyl fumarate versus fingolimod and teriflunomide

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Fingolimod; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2018 Results assessing effect of dimethyl fumarate versus fingolimod and teriflunomide in adult patients with multipe sclerosis, were presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 03 May 2017 New trial record
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top